Hints and tips:
...Sales of a third antiviral made by Japanese pharma company Shionogi are estimated at $0.5bn, down from $2.5bn, because of delays in the approval of the treatment....
...Pfizer is working on a similar drug, as is Japanese drugmaker Shionogi & Co....
...UMN Pharma now stands in negative net worth and under the wing of fellow Japanese pharma company Shionogi....
...The UK recently selected two antimicrobials — made by Japan’s Shionogi and the US’s Pfizer — to be purchased via this Netflix-style subscription payment model....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...‘Perfect scenario’ Those look like V-shaped projections, Andrew Glenn thought to himself....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...It wasn’t an IPO or bond offering, but rather the $11.5bn takeover of Qiagen by Thermo Fisher....
...That compared with $107bn on 177 deals in 2019 — heavily boosted by pharma group Takeda’s completion of its £46bn acquisition of Ireland’s Shire — and $24bn on 152 deals in 2018, according to Dealogic....
...We can move faster than pharma.” Hope for sickle cell Victoria Gray had been ill for all of her 34 years....
...Separately, Merck, the US pharma group, announced results from an early trial for a new treatment for HIV at the conference....
...Germany's telecoms regulator says Huawei can stay in the 5G network race, the European Central Bank faces stimulus pressure over a falling inflation outlook and the FT reports that Purdue Pharma, the makers...
...AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal...
...Ah, so we should also blame big pharma's? And don't forget the FDA!...
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...But this year there have been just two takeovers of a US target company worth more than $5bn, according to figures prepared by Dealogic for the Financial Times — Thermo Fisher’s $7.2bn deal for drug ingredients...
...the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v...
...In Japan, Takeda Pharmaceutical slid 2.7 per cent, Astellas Pharma fell 3.9 per cent and Shionogi sank 3.7 per cent on Thursday morning, while in Australia biotech company CSL Ltd dropped 1.4 per cent and...
...ViiV’s operating profits were up 72 per cent at £1.7bn, compared with a 12 per cent drop in the wider pharma business....
...(FT) Journalism v Silicon Valley The media has lost control of production and distribution to the opaque algorithms of Google and Facebook....
...(Financial Times) Roche is to buy Santaris Pharma for up to $450m in the latest piece of dealmaking by the Swiss pharmaceuticals group....
...These include UK/Prussia v France at Waterloo in 1815, UK/France v Germany between 1914 and 1918 and France/Germany v UK in Brussels ever since 1973....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Examples include Astellas Pharma of Japan’s $3.8bn acquisition of OSI Pharmaceuticals in the US, and Korea National Oil’s $2.8bn deal with Britain’s Dana Petroleum....
...It trumps a $6bn approach by Thermo Fisher , a rival US company, and represents a 50 per cent premium to Millipore’s earlier share price. Thermo Fisher was 0.3 down to $48.65....
International Edition